PharmaCyte Biotech Inc (PMCB) — Cash Flow Quality Index
PharmaCyte Biotech Inc (PMCB) has a Cash Flow Quality Index of -1.05x as of January 2026. Operating cash flow of $-786.85K is below net income of $746.86K, suggesting accrual-heavy earnings not yet converted to cash. Explore PMCB cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
PharmaCyte Biotech Inc Cash Flow Quality Index (2024–2025)
Historical Cash Flow Quality Index for PharmaCyte Biotech Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see PharmaCyte Biotech Inc cash flow conversion.
Annual Cash Flow Quality Index for PharmaCyte Biotech Inc (2024–2025)
Year-by-year earnings quality comparison for PharmaCyte Biotech Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | $-2.98 Million | $30.66 Million | ▲ +98.5% |
| 2024 | -6.45x | $-2.15 Million | $333.76K | — |